Billionaire Stanley Druckenmiller Bets Over 30% of His Portfolio in 3 Stocks

Stanley Druckenmiller is a billionaire hedge fund manager, mainly known for being the lead portfolio manager for George Soros' quantum fund. He uses macroeconomic trends to make his investments and famously "broke the Bank of England" in 1992 by shorting the British pound before Black Wednesday.

George Soros hired him four years earlier to oversee Soros Fund Management. He became the lead portfolio manager for the Quantum fund and its Chief Investment Officer, and although his Bank of England trade made them $1 billion, he left Soros' firm as the Dot Com bubble popped.

Later, he pivoted to managing his own fund, Duquesne Capital Management. It achieved an annual average return of 30% for 30 years, without a single losing year.

Updated on November 27, 2025, with the latest information.

Druckenmiller closed it in 2010 and returned the money to its investors. It had $12 billion in assets, and the performance was stellar, but Druckenmiller found it had a high emotional toll on him. He also found it stressful to manage the money while maintaining his performance.

Druckenmiller may have closed Duquesne Capital Management, but he still operates Duquesne Family Office LLC. Through this, you can track his investments, which have outperformed the market significantly over the past few years. Its top 20 weighted holdings had a cumulative return of 81.63% and an annualized return of 22.01% from 2022 to 2024.

• Total holdings: 62
• Portfolio value: $3.93 billion.
• Q3 2025 performance: 9.07%.
• Top 20 holdings concentration: 72.94%.

• Teva Pharmaceutical is an Israeli company that is now the largest generic drug manufacturer in the world.
• TEVA stock performed poorly in the past, but Druckenmiller has been scooping up theh stock as it traded at a discounted valuation.
• These bets have played out well, with TEVA stock up 48.62% in the past six months alone.
• The company has reduced its debt signiifcantly and Druckenmiller likely sees a full rebound.
• Druckenmiller owns $335.2 million worth of TEVA stock, constituting 8.53% of his portfolio. He has increased his holdings here by 3.91%.

• Insmed is a biopharmaceutical company that makes therapies for rare diseases. The focus is on lung diseases.
• Revenue growth is 52.36% and beat analyst estimates by 23.25%.
• Druckenmiller has been aggressively boosting his stake here.
• Druckenmiller's position here is worth $349 million, or 8.88% of his portfolio. He has increased his holdings by 7.54% in the past quarter.

• Natera is a genetic testing and diagnostics company based in Texas. It has non-invasive products to detect genetic abnormalities in fetuses. It also has a test to track minimal residual disease, with potential applications in tracking cancer recurrence.
• The stock is up 50.88% in the past six months. Q3 revenue increased 34.66% to $592.18 million, and the company beat analyst estimates on the top line by 13.9%.
• Druckenmiller likely expects the company to turn a profit. Analysts predict breakeven in 2026.
• Druckenmiller's NTRA position is worth $517.44 million, or 13.16% of his portfolio. His holdings here have decreased by 4.19%.

Natera has been a consistent and solid growth stock that is quickly approaching profitability. However, it is in an overlooked industry and has flown under Wall Street's radar.

The company's products continue gaining strength, and once it becomes profitable and expands margins, more big investors may notice it on the map. Natera is also an AI-healthcare bet due to the company using it during its genetic testing process.

This billionaire may not be in the spotlight, but he is still investing and managing to outperform the market. Druckenmiller is currently betting on three stocks that are rare to find in the portfolios of any other billionaire, at least not this high up. Perhaps these three could indeed be the winning tickets to trounce the market this year.